BNT326
Sponsors
BioNTech SE
Conditions
Advanced Solid TumorAdvanced solid tumorsNon-small Cell Lung Cancer
Phase 1
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RecruitingNCT07070232
Start: 2025-08-12End: 2029-10-01Target: 980Updated: 2026-03-12
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
RecruitingNCT07111520
Start: 2025-09-22End: 2030-01-31Target: 420Updated: 2025-10-22
A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in participants with advanced solid tumors
RecruitingCTIS2024-517261-16-00
Start: 2025-12-05Target: 172Updated: 2025-10-22
A Phase Ib/II, multi-site, open-label, dose finding trial to evaluate the safety, efficacy, and pharmacokinetics of BNT326 in combination with BNT327 in participants with advanced non-small cell lung cancer (NSCLC)
Not yet recruitingCTIS2024-519344-32-00
Target: 88Updated: 2026-01-27